CO4520254A1 - Vacunas contra tumores y procedimiento para su produccion - Google Patents

Vacunas contra tumores y procedimiento para su produccion

Info

Publication number
CO4520254A1
CO4520254A1 CO96061701A CO96061701A CO4520254A1 CO 4520254 A1 CO4520254 A1 CO 4520254A1 CO 96061701 A CO96061701 A CO 96061701A CO 96061701 A CO96061701 A CO 96061701A CO 4520254 A1 CO4520254 A1 CO 4520254A1
Authority
CO
Colombia
Prior art keywords
patient
tumor cells
peptides
tumor
vaccine
Prior art date
Application number
CO96061701A
Other languages
English (en)
Spanish (es)
Inventor
Schweighoffe Tamas
Walter Schmidt
Max Birnstiel
Peter Steinlein
Michael Buschle
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19543649A external-priority patent/DE19543649C2/de
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of CO4520254A1 publication Critical patent/CO4520254A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO96061701A 1995-11-23 1996-11-22 Vacunas contra tumores y procedimiento para su produccion CO4520254A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19543649A DE19543649C2 (de) 1995-11-23 1995-11-23 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
CO4520254A1 true CO4520254A1 (es) 1997-10-15

Family

ID=26020603

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96061701A CO4520254A1 (es) 1995-11-23 1996-11-22 Vacunas contra tumores y procedimiento para su produccion

Country Status (24)

Country Link
US (1) US20020085997A1 (enExample)
EP (1) EP0866851A1 (enExample)
JP (1) JP2000502052A (enExample)
KR (1) KR19990067653A (enExample)
CN (1) CN1202931A (enExample)
AR (1) AR004341A1 (enExample)
AU (1) AU720131B2 (enExample)
BG (1) BG62999B1 (enExample)
BR (1) BR9611466A (enExample)
CA (1) CA2238176A1 (enExample)
CO (1) CO4520254A1 (enExample)
CZ (1) CZ158998A3 (enExample)
EE (1) EE03778B1 (enExample)
HU (1) HUP0000318A3 (enExample)
NO (1) NO982329D0 (enExample)
NZ (1) NZ322910A (enExample)
PL (1) PL188537B1 (enExample)
RO (1) RO115275B1 (enExample)
RU (1) RU2206329C2 (enExample)
SK (1) SK66998A3 (enExample)
TR (1) TR199800912T2 (enExample)
TW (1) TW514530B (enExample)
UY (2) UY24367A1 (enExample)
WO (1) WO1997019169A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4600681A1 (es) † 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
DE69839273T2 (de) 1997-01-31 2009-03-05 Edward P. Chicago Cohen Krebsimmuntherapie mit semi-allogenen zellen
DE69731950T2 (de) * 1997-08-22 2005-05-19 Science Park Raf S.P.A. Tumorvakzinierung mittels Verwendung autologer oder HLA-verwandter Antigen präsentierender Zellen (APC), die mit einem Tumorantigen sowie einem eine Immunantwort hervorrufenden Fremdantigen transduziert sind
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
WO1999047687A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Enhanced anti-tumor immunity
FR2807661A1 (fr) * 2000-04-14 2001-10-19 Univ Nantes Agent et procede pour la simulation de lymphocytes t specifiques et lymphocytes t obtenus
EP1473564A4 (en) * 2001-09-18 2008-12-10 Greenpeptide Co Ltd METHOD FOR DETECTING CELL IMMUNITY AND ITS APPLICATION TO MEDICAMENTS
RU2203683C1 (ru) * 2001-09-20 2003-05-10 НИИ онкологии им. проф. Н.Н. Петрова Способ иммунотерапии костно-мозговыми дендритными клетками больных солидными опухолями
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
CN1871025B (zh) * 2003-08-25 2013-06-05 杨启明 基于印记位点调节物兄弟(boris)的预防性癌症疫苗
RU2267326C2 (ru) * 2004-03-16 2006-01-10 ГУН НИИ онкологии им. проф. Н.Н. Петрова Минздрава РФ Способ иммунотерапии опухолевым лизатом с адъювантом беталейкин больных солидными опухолями
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
NZ590431A (en) * 2005-02-23 2012-08-31 Genentech Inc Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
WO2006105255A2 (en) 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
ATE461215T1 (de) * 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
MX364370B (es) * 2012-07-12 2019-04-24 Persimmune Inc Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
JP6710004B2 (ja) 2016-03-15 2020-06-17 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
CA3187258A1 (en) 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes
JP2024511950A (ja) * 2021-03-12 2024-03-18 ティー－キュア バイオサイエンス，インコーポレイテッド Ｔｃｒ－ｔ療法に対する腫瘍細胞の感受性を広げるための腫瘍におけるｈｌａハプロタイプ発現の多様性の増強方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
EP0569678A3 (de) * 1992-03-13 1994-10-26 Yeda Res & Dev Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen.

Also Published As

Publication number Publication date
HUP0000318A3 (en) 2002-02-28
US20020085997A1 (en) 2002-07-04
CN1202931A (zh) 1998-12-23
CZ158998A3 (cs) 1999-06-16
AU7694796A (en) 1997-06-11
EE9800161A (et) 1998-12-15
BR9611466A (pt) 1999-05-18
EE03778B1 (et) 2002-06-17
TR199800912T2 (xx) 1998-08-21
KR19990067653A (ko) 1999-08-25
AU720131B2 (en) 2000-05-25
EP0866851A1 (de) 1998-09-30
CA2238176A1 (en) 1997-05-29
AR004341A1 (es) 1998-11-04
TW514530B (en) 2002-12-21
WO1997019169A1 (de) 1997-05-29
BG102439A (en) 1999-01-29
RU2206329C2 (ru) 2003-06-20
PL188537B1 (pl) 2005-02-28
UY24430A1 (es) 1997-07-01
UY24367A1 (es) 2000-10-31
NO982329D0 (no) 1998-05-22
SK66998A3 (en) 1998-12-02
PL326756A1 (en) 1998-10-26
NZ322910A (en) 2000-05-26
HUP0000318A2 (hu) 2000-06-28
JP2000502052A (ja) 2000-02-22
RO115275B1 (ro) 1999-12-30
BG62999B1 (bg) 2001-01-31

Similar Documents

Publication Publication Date Title
CO4520254A1 (es) Vacunas contra tumores y procedimiento para su produccion
ES2317894T5 (es) Procedimiento para la estimulación específica de antígeno de linfocitos T con bibliotecas de péptidos sintéticas
Chase The impact of BVDV infection on adaptive immunity
Childerstone et al. Demonstration of bovine CD8+ T-cell responses to foot-and-mouth disease virus
Macfarlan et al. T cell responses to cleaved rabies virus glycoprotein and to synthetic peptides.
AU778701B2 (en) MUC-1 derived peptides
Nagy et al. Specific binding of K-and I-region products of the H-2 complex to activated thymus-derived (T) cells belonging to different Ly subclasses.
Katz et al. Immunological focusing by the mouse major histocompatibility complex: mouse strains confronted with distantly related lysozymes confine their attention to very few epitopes
BR9306984A (pt) Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo
CY1115749T1 (el) Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια
ES2061500T3 (es) Diagnosis y vacunas de la hepatitis delta su preparacion y uso.
de Visser et al. Tracing and characterization of the low‐avidity self‐specific T cell repertoire
Fern et al. Promiscuous malaria peptide epitope stimulates CD45Ra T cells from peripheral blood of nonexposed donors
DK1448229T3 (da) Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
Bauer et al. Polypeptides of avian RNA tumor viruses: II. Serological characterization
ATE130198T1 (de) Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung.
Sjaastad et al. Reduced T cell priming in microbially experienced “Dirty” mice results from limited IL-27 production by XCR1+ dendritic cells
KR890700030A (ko) 인플루엔자균(Haemophilus influenzae)의 백신 및 진단방법
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
AR009365A1 (es) Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno
AR004567A1 (es) Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.
ES2143996T3 (es) Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.
DE68923286D1 (de) Impfstoffe und testsätze für haemophilus influenzae.
ES2080023A1 (es) Capsidas y proteinas recombinantes del virus de la enfermedad hemorragica del conejo (rhdv), kits de diagnostico y vacunas que contienen dichos productos recombinantes.
ATE109158T1 (de) Rubella-e1 und c peptide.